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Abstract Background:HX575, licensed under the brand names Binocrit, Epoetin Alfa
Hexal, and Abseamed, was approved in 2007 as the first biosimilar recom-
binant human erythropoietin alfa (epoetin alfa) in the EU using Erypo/
Eprex as reference product.
Objectives: The aim of this study was to investigate the bioequivalence and
potency of registered epoetin alfa products that have not been compared
before in a randomized controlled clinical study.
Methods: The study was conducted in two parts: part A compared the
European-marketed HX575 and the US-marketed Epogen; part B com-
pared the European-marketed Erypo/Eprex and HX575 manufactured
at two different drug substance production sites (HX575-TT denoting the
already-approved technology-transfer product from an additional manufac-
turing site). In analyses across both study parts, Epogen was exploratorily
compared with Erypo/Eprex.
A dense-sampling 48-hour pharmacokinetic profile was recorded at steady
state after 11 doses of 100 IU epoetin alfa per kg of bodyweight. The hemo-
globin response over 4 weeks of study medication administration was anal-
yzed as the primary efficacy surrogate parameter using an ANCOVA model
with the baseline value as co-variate.
The per-protocol population comprised a total of 268 subjects, 76 in part A
(equally randomized to HX575 or Epogen) and 192 in part B (equally random-
ized to HX575, HX575-TT, or Erypo/Eprex). Pairs of study arms were com-
pared in terms of the ratio of the mean epoetin alfa area under the curve (AUC)
and the ratio of the mean hemoglobin area under the effect curve (AUEC).
Results: Bioequivalence was shown in all pair-wise comparisons with the 90%
confidence intervals of theAUC ratios fallingwithin the standard bioequivalence
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limits of 80–125%. Moreover, an equivalent pharmacodynamic response was
achieved with all compared epoetin alfa products, as confirmed by the he-
moglobin AUEC ratio’s 90% CI falling within the predefined acceptance
margins of 96.8–103.2%. Thus, bioequivalence and equivalent potency was
demonstrated for HX575 and Epogen in part A of the study, as well as for
HX575, HX575-TT and Erypo/Eprex in part B of the study. Pair-wise
comparison across study parts indicated similar pharmacokinetic and phar-
macodynamic profiles of Epogen and Erypo/Eprex.
All compared epoetin alfa products were well tolerated and had a similar
safety profile. No subject developed anti-erythropoietin antibodies upon
administration of study medication.
Conclusion: The results show, for the first time in a prospective randomized
clinical study, equivalent bioavailability at steady state and similar potency of
the US-marketed Epogen and the European-marketed Binocrit. Differ-
ences in the formulation between the epoetin alfa products had no apparent
clinical impact. The high degree of similarity between Epogen and Erypo/
Eprex provides justification for linking and comparing results from clinical
studies that were conducted using either US- or European-marketed epoetin
alfa products.
Introduction
Hypoxia and anemia induce the production
of endogenous erythropoietin in the kidneys of
healthy individuals, which, in turn, stimulates
erythropoiesis.[1] The molecular biology of eryth-
ropoietin preventing the programmed cell death
of erythrocytic progenitors was reviewed by
Jelkmann.[2] Erythropoiesis stimulating agents,
such as epoetin alfa, are indicated for the cor-
rection of anemia in patients with chronic renal
failure who have an impaired production of en-
dogenous erythropoietin, and in patients with
chemotherapy-induced anemia. In addition, epoe-
tin alfa reduces the need for blood transfusions in
patients scheduled to undergo surgery, and can
also be used for patients at risk for perioperative
transfusions with anticipated significant blood
loss.
Epoetin alfa products have been used in clin-
ical practice for more than two decades. Erypo/
Eprex (Janssen-Cilag, a subsidiary of Johnson
& Johnson, New Brunswick, NJ, USA), was the
first epoetin alfa that received regulatory appro-
val in Europe in 1988. Epogen received appro-
val in the US in 1989 and is marketed in the US by
Amgen (Thousand Oaks, CA, USA) for treat-
ment of anemia in patients undergoing hemo-
dialysis and by Johnson & Johnson, under the
name of Procrit. In Europe, the stabilizer in
Erypo/Eprex was changed from human serum
albumin (HSA) to a synthetic compound, poly-
sorbate 80 in 1998, and subsequently only HSA-
free epoetin alfa products have been available in
Europe.[3] In other regions (Canada, Singapore, and
Australia), both HSA-free and HSA-containing
Eprex are marketed and comparative studies
showed that both formulations are bioequiva-
lent.[4] Other epoetin alfa products have not
undergone formulation changes, and the US-
marketed Epogen/Procrit still uses a HSA-
containing buffer.[5,6]
The present study in healthy volunteers in-
vestigated the comparability of three marketed
epoetin alfa products with respect to bioequiva-
lence and pharmacodynamic activity at steady
state following multiple intravenous administra-
tions. To our knowledge, this was the first head-
to-head comparison of epoetin alfa products
across different geographic regulatory regions:
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Epogen, marketed in the US, and HX575 and
Erypo/Eprex both marketed in Europe. The
goals of this large, two-part, phase I study were to
provide bridging data for an extension of the
HX575 marketing authorization, and to establish
the clinical equivalence of HX575 from two dif-
ferent sources, following the transfer of the pro-
duction technology from the drug substance
manufacturer Rentschler Biotechnologie GmbH,
Laupheim, Germany, to an additional, already-




This randomized, parallel-group study was
conducted at Nuvisan GmbH (formerly AAI-
Pharma Deutschland GmbH & Co. KG), Neu-
Ulm, Germany, and consisted of two parts. In
part A, HX575 was compared with Epogen;
part B consisted of three arms: HX575, HX575-TT
(denoting the already-approved technology-
transfer product from an additional manufactur-
ing site), and Erypo/Eprex.
Eligible subjects were healthy male Cau-
casians, aged 18–50 years, with a bodyweight
of £100 kg, and a body mass index between 18
and 30 kg/m2. Healthy males were chosen for
the study population for methodologic consid-
erations, such as the absence of a risk of preg-
nancy and the lower metabolic variability due to
the absence of a menstrual cycle. Regarding
the Caucasian disposition, there is much evi-
dence to suggest that two formulations that
were bioequivalent in one study population will
also be bioequivalent in other populations.[7]
Subjects had to be physically and mentally
healthy as confirmed by an interview, medical
history, clinical examination, laboratory tests,
and electrocardiogram.
Other inclusion criteria were hemoglobin
concentrations between 13.0 and 15.5 g/dL, and
percentage of reticulocytes £3.0% at screening.
Iron parameters had to be normal or with only
minor deviations, with iron deficiency defined as
ferritin concentrations below 10.0 ng/mL.
Subjects were not eligible for enrollment if
their medical history or examination showed evi-
dence of acute or chronic hepatic, renal, gastro-
intestinal, cardiovascular, pulmonary, hematologic,
or other abnormalities that might influence the
absorption, distribution, metabolism, or excre-
tion of the active agent under investigation. Fur-
ther exclusion criteria were hypersensitivity to
drugs, presence of atopic eczema, or allergic bron-
chial asthma; evidence of cardiovascular disorders,
particularly hypertension (supine blood pressure
>145/90mmHg at baseline); or increased numbers
of erythrocytes, or platelets, if judged by the inves-
tigator to be clinically relevant.
Abuse of alcohol, caffeine, or tobacco was an
exclusion criterion, and smoking was limited to a
maximum of ten cigarettes per day. Regular use
of any medication within 4 weeks, as well as sys-
temic androgen application within 2 months prior
to the first dose of study drug, was prohibited.
Moreover, the single use of any medication in-
cluding over-the-counter medications was prohi-
bited, unless expressively permitted, within 2 weeks
prior to the first study drug administration.
All subjects had to sign an informed consent
form before the first invasive screening examina-
tion was performed. The study was approved
by an independent ethics committee, and was
conducted in accordance with the Declaration
of Helsinki, Good Clinical Practice and Good
Laboratory Practice guidelines.
Administration of Study Medication
Eligible subjects were enrolled in one of the
two study parts. Subjects in part A were random-
ized (1 : 1) to receive either HX575 or Epogen.
Subjects in part B were randomized (1 : 1 : 1) into
one of three study arms, to receive HX575,
HX575-TT, or Erypo/Eprex. All subjects re-
ceived intravenous injections of epoetin alfa of
100 IU/kg bodyweight three times weekly for
4 weeks. The selected dosage represented normal
therapeutic doses and followed regimens of a
previous phase I clinical trial.[8] Study medication
was administered in the forearm vein in the
morning of study days 1, 3, 5, 8, 10, 12, 15, 17, 19,
22, 24, and 26.
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A non-investigational oral iron supplement
[ferrous(II)-glycine-sulphate complex, ferro sanol
duodenal, Schwarz Pharma AG, Germany;
100mg twice daily] was given to all subjects for
self-intake during epoetin alfa treatment.
Any other concomitant medication was lim-
ited to what might have been indicated for the
treatment of adverse events; beside that, only
ibuprofen up to 800mg/day or paracetamol up to
2000mg/day were allowed from the screening
visit until the last follow-up visit.
Third-party blinding of the treatment was ap-
plied in this study (i.e. the different study medi-
cations were transferred from their individual
primary packaging into identical syringes by a
pharmacist). Investigators applying the study treat-
ment and subjects remained blind to the treatment.
Blood Sampling
Blood samples (4.9mL) for the assessment of
serum epoetin alfa concentrations were drawn
on day 1 at -30, -20, -10 minutes pre-dose, and
just before administration, and on days 8, 15, 19,
and 22 (0 to £15 minutes before dosing). Dense
sampling was performed on day 24 at -30, -20,
-10 minutes before dosing, just before dosing,
and at 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2,
3, 4, 6, 8, 10, and 12 hours after dosing, and on
days 25 (16 hours and 24 hours after dosing) and
26 (i.e. 48 hours after day 24 dosing but prior to
day 26 dosing).
Blood sampling (2.7mL) for the analysis of
pharmacodynamic parameters was scheduled on
day 1 (-30, -20, -10 minutes, and just before first
dose), and on days 3, 5, 8, 10, 12, 15, 17, 19, 22,
24, 26 (i.e. 48 hours after day 24 dosing), and on
day 29 (i.e. 120 hours after day 24 dosing). For
determination of transferrin, transferrin receptor,
ferritin, and serum iron concentrations, venous
blood samples (4.9mL) were collected at baseline
and on days 12, 19, and 26; in addition, ferritin
and transferrin concentrations were also assessed
at screening and at the follow-up visit.
Blood serum samples of 4.9mL were screened
for anti-erythropoietin antibodies taken on
day 1 (before first dose), day 15, day 29, and at
follow-up.
Blood serum samples for the assessment of
potential anti-erythropoietin antibodies where
shipped to the sponsor’s bioanalytical laboratory
(Hexal AG, Oberhaching, Germany). All other
laboratory assessments were performed by the
clinical laboratory at the study site.
Pharmacokinetic Analyses and Evaluations
Epoetin alfa serum concentrations were quan-
titatively determined by means of a sandwich en-
zyme immunoassay technique (Quantikine IVD,
R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany), which did not discriminate between
endogenous erythropoietin and recombinant
epoetin alfa. The procedure was validated ac-
cording to current guidelines for method vali-
dation and the applied regulations. The calibration
range was from 2.5 to 200.0mIU/mL; the defined
lower limit of quantification was 2.62mIU/mL.
Samples with expected high levels where di-
luted with a dilutant provided with the kit; no
further sample work-up was necessary. The in-
ter-day accuracy and precision data were cal-
culated from 578 sets of quality control samples
in 288 runs. The accuracy (expressed as bias)
ranged between -4.3% and 2.0%; the precision
(expressed as coefficient of variation [CV]) ranged
between 4.5% and 5.5%. During the validation
process, it was also confirmed that the assay de-
tected the different epoetin alfa products with
similar accuracy.
Two samples each from ten subjects were an-
alyzed as incurred samples to demonstrate the
reproducibility of the used method. The evalu-
ation of the data resulted in a mean ratio of 0.974
with ratio limits of 0.942 and 1.01. The lower
limit of agreement was calculated with 0.903, the
higher one with 1.05. All investigated samples lay
within the acceptable limits of agreement. The
acceptance ranges for both of the ratio limits, as
well as the limits of agreement, were met.
Pharmacokinetic endpoints were calculated by
non-compartmental analyses based on the deter-
mined epoetin concentrations and actual measured
sampling times. The primary pharmacokinetic end-
point was the epoetin area under the 48-hour serum
concentration-time curve on day 24 (AUCt,D24)
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at steady state, which was a multiple-dose phar-
macokinetic assessment starting on study day 24.
Two epoetin alfa products were considered bio-
equivalent if the ratio’s 90% CI fell within the
standard acceptance limits of 80–125%. Second-
ary exploratory endpoints were maximal con-
centration (Cmax) and time to Cmax (tmax). The
mean of the four pre-dose pharmacokinetic
samples at day 24 was the baseline value for the
calculation of the AUCt,D24.
Pharmacodynamic Assays and Evaluations
The time course of hemoglobin concentration
was evaluated as the primary surrogate marker
for efficacy. The pharmacodynamic action was
determined as the area under the total effect curve
(AUEC) during 12 dosage intervals in 4 weeks,
which were calculated by linear trapezoidal in-
tegration. Equivalence of two study medications
was assumed if the hemoglobin AUEC ratio’s
90%CI fell within predefined acceptance limits of
96.8–103.2%.
The rationale for the hemoglobin AUEC ac-
ceptance limits was based on previous study re-
sults.[8] It was anticipated that the hemoglobin
concentration would increase by approximately
3 g/dL within 4 weeks of treatment. A difference
of –1 g/dL was considered acceptable because
under clinical conditions of tightly monitored
hemoglobin concentrations, no dose adjustment
is required if the hemoglobin concentration is
within 1 g/dL of the target. Also, in clinical stud-
ies a threshold of –1.0 g hemoglobin/dL has been
used as the greatest clinically acceptable differ-
ence to demonstrate equivalence.[9]
The secondary pharmacodynamic parameters
of red blood cells, haematocrit, and absolute and
relative reticulocytes concentrations were evaluated
exploratorily without predefined equivalence ranges,
using the standard acceptance limits of 80–125%
for the 90% CI of the AUEC ratios.
Screening for Anti-Erythropoietin Antibodies
Blood samples were screened for anti-eryth-
ropoietin antibodies using a validated radio-
immunoprecipitation (RIP) assay. In case of a
positive RIP assay result, the sample was anal-
yzed for neutralizing anti-erythropoietin anti-
bodies (NAB) using a validated in vitro bioassay.
Safety Assessments
Adverse events were spontaneously reported
by the subjects or solicited by non-leading ques-
tions of the investigator. Vital signs were assessed
at every study visit. Physical examinations and
ECG evaluations were performed at screening and
at the end-of-study visit. Standard laboratory
evaluations were performed at the first and the last
study visit. The investigator decided whether an
abnormality represented an adverse event.
Statistical Methods
Both study parts were analyzed separately by
using identical statistical methods. All evalua-
tions were carried out as predefined in a statistical
analysis plan. Statistical analysis of the clinical
data was performed by Metronomia Clinical
Research GmbH, Munich, Germany. All phar-
macokinetic endpoints were derived using ap-
propriate pharmacokinetic software (PCModfit,
version 3.0). All statistical calculations were per-
formed using SAS software (version 9.1.3). Ad-
verse events were coded using MedDRA (version
11.0). Previous and concomitant medications
were coded according to the WHO Drug Dic-
tionary (version 2008).
The two primary endpoints for confirmatory
analyses were (i) the epoetin AUCt,D24, which
was a multiple-dose pharmacokinetic assessment
over 48 hours starting on day 24; and (ii) the ab-
solute hemoglobin response assessed as AUEC
over 4 weeks. Secondary pharmacokinetic end-
points (Cmax and tmax of epoetin), and secondary
pharmacodynamic endpoints (hemoglobin, maxi-
mal effect [Emax], and time to Emax [tmax,E]) and
other hematological parameters, such as hema-
tocrit, reticulocyte, and erythrocyte counts, were
analyzed.
The sample size and power considerations were
based on the expectation of an inter-individual
CV of about 3.8% for the log-transformed AUEC
of hemoglobin.[10] The 90%CI of the AUEC ratio
was to be included by a range of 96.8–103.2%,
provided the true ratio was within 99% and 101%.
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Pair-wise comparisons were performed in a pre-
defined hierarchical order. In part A, 37 sub-
jects per treatment group had to complete the
study according to protocol (i.e. to be included
in the per-protocol set) in order to have a power
of 80% and to determine the relative pharma-
codynamic efficiency in terms of the AUEC
ratio with an adequate precision (i.e. in an anal-
ogous way to a bioequivalence study). In part B,
63 evaluable subjects per treatment group was
sufficient to have a power of 95% for the pri-
mary comparison between HX575-TT and
HX575, and a power of approximately 90% to test
HX575-TT versus Erypo/Eprex. The compar-
ison between both reference epoetin alfa products
(Erypo/Eprex and Epogen) was performed
exploratorily.
Based on results from a previous study with
HX575,[8] a CV of 20–25% for the primary phar-
macokinetic endpoint AUCt,D24 was expected.
The corresponding sample size necessary to con-
firm bioequivalence between any pair of study
medication tested in this study within the stan-
dard acceptance limits of 80–125% and with a
power of at least 80%, amounted to at least
27 evaluable subjects. Therefore, the sample size
determined for the comparison of the primary
pharmacodynamic endpoint was also sufficient
for a proper pharmacokinetic bioequivalence
assessment.
The mean, standard deviation, coefficient of
variation, range and median, were calculated for
each parameter. The geometric mean and its co-
efficient of variation were also determined for
concentration-related parameters. For AUEC,
Emax, AUC, and Cmax, the parametric point esti-
mators for the ratio and the shortest 90%CI were
calculated using the least square means and the
root of residual mean squares from the ANOVA
of log-transformed data with subsequent ex-
ponential transformation.[11]
The primary pharmacokinetic and pharmaco-
dynamic analyses were based on the per-protocol
set, which excluded major protocol violators. The
decision on the exclusion of individual subjects
from the per-protocol set was taken at the blind
data review meeting. In order to investigate the
robustness of the results with regard to the pri-
mary pharmacodynamic endpoint, the analyses
were also performed on all study completers
(data not shown).[12]
ANOVA were to be performed on all end-
points except tmax. In case of substantial differ-
ences between treatment groups in a key baseline
value, such as the hemoglobin level, an analysis of
co-variance (ANCOVA) was performed, includ-




A total of 307 healthy adult males were en-
rolled and randomized – 87 in part A and 220 in
part B. Seventy-eight subjects in part A and 200
subjects in part B completed the study. The study
attrition and the number of subjects finalizing the
study are summarized in figure 1.
In part A, nine subjects withdrew prematurely
from the study, including two subjects who were
withdrawn before the first administration of
study medication (the reported reasons were ‘poor
vein condition’ and ‘high blood pressure’, re-
spectively). One subject in the HX575 arm and
two subjects in the Epogen arm discontinued
the study because of adverse events (nasophar-
yngitis in two subjects; one subject was phlebo-
tomized and discontinued the study because of
increased hematocrit [57.2%] and increased
hemoglobin [11.4mmol/L= 18.37 g/dL]). Four sub-
jects withdrew without indicating specified rea-
sons, other than adverse events. In part B, one
subject discontinued the study because of an
adverse event (fever and asthenia, unrelated to
study medication); 19 subjects had to be with-
drawn due to a technical error in the random-
ization procedure (i.e. they were administered
by mistake the incorrect study medication devi-
ating from the randomization scheme) and were
replaced in order to achieve target enrollment
numbers.
Demographic characteristics for all subjects
who received at least one dose of study med-
ication, i.e. the population for safety analyses, are
summarized in table I. Indicative of a successful
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randomization, the demographic characteristics
were comparable between the study arms.
The blinded-data review identified the follow-
ing major protocol violations or implausible
laboratory values (these were mainly pharma-
cokinetic profiles that suggested an accidental
non-intravenous administration route) leading to
exclusion of ten subjects from the per-protocol
set. In part A, two subjects were excluded: one
subject in the Epogen arm because of implau-
sible pharmacokinetic values and one subject in
the HX575 arm because of iron deficiency despite
supplementary iron treatment. In part B, eight
subjects were excluded (HX575: two, HX575-TT:
one, Erypo/Eprex: five), five of whom because
of implausible pharmacokinetic values, two sub-
jects because they received incorrect study med-
ication by mistake at one visit, and one subject
because of iron deficiency despite supplementary
iron treatment. All prematurely withdrawn sub-
jects were also excluded from the per-protocol set.
Thus, the per-protocol set included 76 subjects in
part A (HX575: 38, Epogen: 38), and 192 sub-
jects in part B (HX575: 65, HX575-TT: 65, and
Erypo/Eprex: 62).
Pharmacokinetic Results
The small differences between study arms
at baseline had no influence on the AUC. The
pre-dose concentration of endogenous erythro-
poietin at day 24 ranged from a mean (– SD)
of 7.21 – 3.208mIU/mL to 8.77 – 6.618mIU/mL.
The epoetin alfa concentration versus time profiles
were similar for all study arms in both parts of the
study as shown in figure 2. For this analysis, the
HX575 data from both study parts were pooled.
The mean epoetin concentrations in all study
arms reached their peak at 5 minutes after ad-
ministration (the median tmax of epoetin levels
was 0.083 hours). The key summary results for


















• Subject’s request (n = 4)
• AE (n = 3)
• Investigator (n = 1)1






















• Subject’s request (n = 0)
• AE (n = 1)
• Investigator (n = 0)
• Other (n = 19)
Part A Part B
Fig. 1. Subject randomization and analysis populations. 1 Two randomized subjects in part A were not treated and were withdrawn from the
study for the following reported reasons: ‘high blood pressure pre-dose’ and ‘poor vein conditions’.AE = adverse event; PV =protocol violation;
VCS = valid cases set for pharmacokinetic and pharmacodynamic analyses.
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table II. The primary analyses, the pair-wise com-
parisons of the mean AUCt,D24 between study
arms within either study part and across study
parts, are shown in table III.
In part A of the study, HX575 and Epogen
were shown to be bioequivalent: the 90% CI of
the AUCt,D24 ratio was well within the standard
bioequivalence limits of 80–125%. In part B of
the study, bioequivalence was shown for HX575
and HX575-TT. Moreover, HX575-TT and
Erypo/Eprex also met the bioequivalence cri-
teria. In a further step, the confirmative com-
parison across both parts of the study showed
bioequivalence of HX575-TT and Epogen, and
the exploratory comparison across both study
parts indicated bioequivalence of both reference
products, Epogen and Erypo/Eprex. Pharma-
cokinetic equivalence could thus be shown for all
pair-wise compared epoetin alfa products.
The comparison of the secondary pharmaco-
kinetic endpoints supported the finding of bio-
equivalence, with the 90% CI of the Cmax ratios
for all compared epoetin alfa products being
well within the standard acceptance margins.
Trough concentrations were similar in all study
arms (ranging from 5.79mIU/L to 6.60mIU/L).
Cmax values were also comparable in all treat-
ment arms, although they tended to be slightly
higher with HX575-TT, Epogen and Erypo/
Eprex than with HX575 in both parts of the
study (see table II). The median tmax was identical
in all study arms (5 minutes) and median half-life
ranged from 3.17 to 3.32 hours.
Pharmacodynamic Results
Pre-dose baseline values for the hematologic
parameters differed between treatment groups
and study parts to such an extent that it impacted
on the derived endpoints, especially the AUEC
results. Thus, and as predefined in the protocol,
pharmacodynamic data were analyzed using
the ANCOVA model with the baseline value as
co-variate. The baseline values for the primary
pharmacodynamic parameter hemoglobin were
as follows in part A: HX575 14.57 – 0.71 g/dL,
Epogen 14.78 – 0.45 g/dL; and in part B: HX575
14.72 – 0.57 g/dL, HX575-TT 14.91 – 0.59 g/dL,
Erypo/Eprex 14.82 – 0.61 g/dL.
A comparable mean hemoglobin concentra-
tion over time course was achieved with all stud-
ied epoetin alfa products, as shown in figure 3.
All pair-wise comparisons of the studied
epoetin alfa products indicated pharmacodynam-
ic equivalence in terms of the mean hemoglobin
response: The 90% CI of the point estimates were
completely within the predefined acceptance
limits of 96.8–103.2% (see table IV).
The exploratory comparison of the secondary
hemoglobin endpoints supported the finding of
pharmacodynamic equivalence. The hemoglobin
Emax ratios’ 90% CIs were also within the
standard equivalence limits for all comparisons
Table I. Demographic characteristics
Parameter Mean SD Range
Part A (n =85)
HX575 (n= 41)
age (y) 36.4 8.7 20–50
weight (kg) 77.10 10.19 59.2–98.0
BMI (kg/m2) 24.54 2.65 19.3–29.7
height (m) 1.77 0.064 1.66–1.91
Epogen (n =44)
age (y) 35.5 9.8 18–50
weight (kg) 77.13 9.44 55.0–99.8
BMI (kg/m2) 24.51 2.65 19.0–29.5
height (m) 1.77 0.068 1.63–1.90
Part B (n =220)
HX575 (n= 74)
age (y) 35.7 8.8 19–48
weight (kg) 75.83 8.54 59.7–100.00
BMI (kg/m2) 23.66 2.08 19.3–27.9
height (m) 1.790 0.072 1.63–1.97
HX575-TT (n =73)
age (y) 36.2 8.9 19–50
weight (kg) 78.33 9.69 55.9–99.0
BMI (kg/m2) 24.21 2.72 18.6–29.9
height (m) 1.799 0.070 1.63–1.93
Erypo/Eprex (n =73)
age (y) 34.7 9.6 18–50
weight (kg) 77.67 9.49 54.5–99.7
BMI (kg/m2) 24.35 2.72 18.1–29.8
height (m) 1.786 0.060 1.64–1.93
BMI = body mass index.
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(table V). The median tmax,E was identical in both
study arms in part A: 599.83 hours (HX575),
599.83 hours (Epogen); and comparable in part B:
599.83 hours (HX575), 551.97 hours (HX575-TT),
































Time (hours from morning dosing on day 24)
−2 0 2 4 6 8 10 12 14 16 18 20 22 24
Fig. 2. Mean serum epoetin concentrations over time (parts A and B combined). HX575 data from both study parts were pooled for this
analysis. Per-protocol set parts A and B combined (n =268), HX575 (n =103), HX575-TT (n = 65), Epogen (n= 38), and Erypo/Eprex
(n= 62).
Table II. Epoetin area under the 48-hour serum concentration-time curve on day 24 (AUCt,D24)
a and maximum concentration (Cmax) after
multiple intravenous epoetin doses
Parameter Mean SD GeoM Minimum Median Maximum
AUCs,D24 [mIUh/mL]
Part A
HX575 (n =38) 8459 1243.3 8378 6713 8378 12986
Epogen (n = 38) 9373 1380.9 9262 5213 9601 11401
Part B
HX575 (n =65) 7709 1153.0 7626 5401 7495 10338
HX575-TT (n = 65) 8835 1094.4 8768 6298 8873 11706
Erypo/Eprex (n =62) 9625 1718.4 9483 6701 9077 14982
Cmax [mIU/mL]
Part A
HX575 (n =38) 1959 239.2 1944 1220 1960 2 600
Epogen (n = 38) 2008 282.1 1987 1190 2030 2 560
Part B
HX575 (n =65) 1884 273.4 1865 1330 1870 2 870
HX575-TT (n = 65) 2155 274.7 2138 1630 2140 2 910
Erypo/Eprex (n =62) 2070 269.5 2052 1460 2035 2 590
a The AUCt,D24 is the result of multiple-dose pharmacokinetic assessments starting on study day 24 (i.e. at steady state) and was the primary
pharmacokinetic endpoint.
GeoM = geometric mean.
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The evaluation of all secondary hematologic
parameters was also in line with the results of the
confirmatory analysis of hemoglobin, and sup-
ported the finding of equivalent pharmacodynam-
ic potency. The concentration over time curves of
hematocrit, erythrocytes, and relative and abso-
lute reticulocytes showed similar courses, with
the exception of the time curves for reticulocyte
counts, which showed a slightly diverging trend
during the first 8 days, followed by a subse-
quently parallel course (data not shown).[12] For
all pair-wise comparisons between the study arms
of hematocrit, erythrocytes, and relative and ab-
solute reticulocytes AUEC and Emax the 90% CIs
of the ratios were within the standard bioequiva-
lence boundaries of 80–125%, although no formal
equivalence criteria were predefined (table VI).
Safety
There were no clinically relevant differences
among the studied epoetin alfa products (HX575,
HX575-TT, Epogen, and Erypo/Eprex) with
regard to frequency or type and severity of ad-
Table III. Confirmatory comparisons showing the epoetin area under the concentration-time curve (AUC) ratios and 90% confidence intervals
(CIs)
Pair-wise comparison Ratio (%) of the geometric mean AUC and [90% CI]a ANOVA-CV (%)
Part A (n =76)
HX575 vs Epogen 90.46 [85.41, 95.81] 15.11
Part B (n =192)
HX575-TT vs HX575 114.98 [110.49, 119.66] 13.77
HX575-TT vs Erypo/Eprex 92.46 [88.49, 96.62] 15.03
Parts A and B combined (n =268)
HX575-TT vs Epogen 94.67 [90.30, 99.25] 14.00
Epogen vs Erypo/Eprexb 97.67 [92.2, 103.45] 16.94
a Bioequivalence limits 80–125%.
b Exploratory comparison.
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Fig. 3. Mean hemoglobin concentration over time (parts A and B combined). HX575 data from both study parts were pooled for this analysis.
Per-protocol set parts A and B combined (n =268), HX575 (n =103), HX575-TT (n = 65), Epogen (n= 38), and Erypo/Eprex (n =62).
Scr. = screening.
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verse events. Results from the laboratory tests,
assessment of vital signs and physical examina-
tions confirmed the absence of marked changes in
subjects’ state of health. Product-related adverse
events observed in this study during HX575,
HX575-TT, Epogen, and Erypo/Eprex treat-
ment were as expected for treatment with any
erythropoietin stimulating agent (ESA). The ma-
jority of observed adverse events were mild and
all adverse events resolved until the last post-
study examination.
The changes seen in ferritin and soluble
transferrin receptor levels are in line with effects
of ESA treatment and the measured effects were
similar across all study arms. Ferritin levels de-
creased in all study arms, showing that despite the
iron supplement, the body storage of iron de-
creased with ongoing epoetin alfa therapy.
Table IV. Hemoglobin area under the effect curve (AUEC)a and maximal effect (Emax) after multiple intravenous epoetin doses
Parameter Mean SD GeoM Minimum Median Maximum
AUEC [gh/dL]
Part A
HX575 (n =38) 10 476 417.3 10 468 9316 10 549 11 180
Epogen (n = 38) 10 740 373.7 10 734 9877 10 708 11 394
Part B
HX575 (n =65) 10 649 (365.3) 10 643 9823 10 662 11 315
HX575-TT (n = 65) 10 755 (323.1) 10 750 9952 10 744 11 409
Erypo/Eprex (n =62) 10 739 (311.4) 10 734 9853 10 702 11 427
Emax [g/dL]
Part A
HX575 (n =38) 16.7 0.63 16.7 14.8 16.8 18.2
Epogen (n = 38) 17.2 0.82 17.1 15.5 17.1 20.1
Part B
HX575 (n =65) 16.9 0.66 16.9 15.3 16.9 18.2
HX575-TT (n = 65) 17.0 0.58 17.0 15.8 17.1 18.7
Erypo/Eprex (n =62) 17.1 0.53 17.1 16.0 17.2 18.5
a The AUEC reflects the absolute hemoglobin response over 4 weeks of study medication administration and was the primary
pharmacodynamic endpoint.
GeoM = geometric mean.
Table V. Confirmatory comparisons showing the hemoglobin area under the effect curve (AUEC) ratios with 90% confidence intervals (CIs)
Pair-wise comparison Ratio (%) of geometric mean AUC and [90% CI]a ANCOVA-CV (%)
Part A (n =76)
HX575 vs Epogen 98.48 [97.51, 99.47] 2.57
Part B (n =192)
HX575-TT vs HX575 100.23 [99.59, 100.89] 2.21
HX575-TT vs Erypo/Eprex 99.83 [99.26, 100.41] 1.96
Parts A and B combined (n =268)
HX575-TT vs Epogen 99.58 [98.87, 100.30] 2.10
Epogen vs Erypo/Eprexb 100.18 [99.42, 100.94] 2.21
a Predefined equivalence limits 96.8–103.2%.
b Exploratory comparison.
ANCOVA-CV =analysis of co-variance – coefficient of variation.
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Overall, 1168 samples were screened for anti-
erythropoietin antibodies. Two subjects had
positive RIP results prior to the first dose of study
medication, but the NAB assay gave negative
results at all timepoints showing that the anti-
bodies were non-neutralizing. No subject developed
anti-erythropoietin antibodies upon administration
of study medication, and no neutralizing anti-
erythropoietin antibodies were detected in any of
the subjects.
Discussion
Recombinant epoetin alfa products share the
same amino acid sequence as the endogenous
erythropoietin but may vary in the pattern of iso-
forms. For instance, subtle structural differences
in protein conformations can be detected between
Epogen and Eprex by means of biophysical
analyses,[13] but these do not translate into clin-
ically relevant differences. The regulatory point
Table VI. Area under the effect curve (AUEC) ratios of secondary hematologic parameters hematocrit, erythrocytes, and relative and
absolute reticulocytes
Parameter Geometric mean Ratio and [90% CI]a (%)
Part A
HX575 (n = 38) Epogen (n =38)
Hematocrit [Lh/L] 315 322 98.53 [97.53, 99.54]
Erythrocytes [Th/L] 3551 3588 99.10 [98.12, 100.09]
Reticulocytes (rel.) [%h] 1236 1448 88.30 [83.71, 93.14]
Reticulocytes (abs.) [Th/L] 65.45 77.54 87.13 [82.37, 92.15]
Part B
HX575-TT (n =65) HX575 (n = 65)
Hematocrit [Lh/L] 322 317 100.44 [99.78, 101.10]
Erythrocytes [Th/L] 3646 3558 100.23 [99.50, 100.96]
Reticulocytes (rel.) [%h] 1364 1255 103.54 [99.77, 107.46]
Reticulocytes (abs.) [Th/L] 74.11 66.57 104.91 [100.91, 109.07]
HX575-TT (n =65) Erypo/Eprex (n = 62)
Hematocrit [Lh/L] 322 322 99.81 [99.22, 100.40]
Erythrocytes [Th/L] 3646 3614 99.85 [99.13, 100.56]
Reticulocytes (rel.) [%h] 1364 1363 94.15 [90.32, 98.15]
Reticulocytes (abs.) [Th/L] 74.11 73.45 94.36 [90.31, 98.59]
Parts A and B combined
HX575-TT (n =65) Epogen (n = 38)
Hematocrit [Lh/L] 322 322 99.38 [98.66, 100.10]
Erythrocytes [Th/L] 3646 3588 99.81 [99.05, 100.57]
Reticulocytes (rel.) [%h] 1364 1448 92.93 [88.77, 97.29]
Reticulocytes (abs.) [Th/L] 74.11 77.54 93.43 [89.14, 97.94]
Epogen (n = 38) Erypo/Eprex (n = 62)
Hematocrit [Lh/L] 322 322 100.32 [99.58, 101.07]
Erythrocytes [Th/L] 3588 3614 100.08 [99.21, 100.96]
Reticulocytes (rel.) [%h] 1448 1363 100.32 [95.45, 105.44]
Reticulocytes (abs.) [Th/L] 77.54 73.45 100.05 [94.99, 105.38]
a ANCOVA using the mean baseline value as the co-variate; exploratory comparisons using the standard acceptance limits of 80–125%,
although no formal equivalence criteria were predefined.
abs. =absolute counts; rel. = relative counts.
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of view towards biosimilar recognizes the fact
that some differences between similar biologic
medicinal products from different manufacturers
can be expected, which is considered acceptable if
comparable efficacy and safety profiles can be
demonstrated.
HX575 was developed by Sandoz and first
approved in Europe as a biosimilar product
(using the innovator epoetin alfa product Erypo/
Eprex as reference product) following the dem-
onstration of similar quality, safety, and efficacy
profiles in 2007. Clinical studies compared the
pharmacokinetic and pharmacodynamic proper-
ties of different strengths and administration routes
of HX575 and Erypo/Eprex in healthy volun-
teers.[8,14,15] The efficacy and safety of HX575
in the treatment of patients with chronic kidney
disease was assessed in comparison with Erypo/
Eprex,[16] and further safety data were provided
in a comparative study in patients experiencing
chemotherapy-induced anemia.[17]
The present two-part study provides suppor-
tive bridging data for a further extension of the
HX575 marketing authorization and compared
HX575 from two different manufacturing sites.
The second study part had a larger study popu-
lation allowing for two confirmatory pair-wise
comparisons with sufficient statistical power.
Both study parts evaluated the following two
primary endpoints as surrogates for efficacy of
epoetin alfa in sequential pair-wise comparisons
between study arms in a statistically confirm-
atory manner: (i) the bioavailability in terms of
the epoetin alfa AUC; and (ii) potency in terms
of the hemoglobin AUEC. An additional ex-
ploratory assessment compared the two reference
epoetin alfa products Epogen and Erypo/
Eprex.
The differences between the study arms in
baseline concentrations of endogenous erythro-
poietin were negligible and had virtually no ef-
fect on the results in terms of AUC and Cmax. In
contrast, the observed hemoglobin baseline dif-
ferences between the study arms in study part A
had a substantial effect on the AUECs and would
have reduced the statistical power to demonstrate
pharmacodynamic equivalence for HX575 and
Epogen based on the AUEC ratio. Therefore,
the use of the ANCOVA with the baseline he-
moglobin value as co-variate was considered as
the only valid analysis of the pharmacodynamic
endpoints.
Both study parts were well powered to provide
results with sufficient overall statistical signif-
icance and, in conclusion, all study objectives
were met. For all comparisons in both study parts
and also across both study parts, bioequivalence
at steady state was established using standard
acceptance limits for the epoetin AUC ratios, and
equivalent pharmacodynamic responses were
demonstrated based on very narrow predefined
acceptance limits for the hemoglobin AUEC
ratios. The results of the secondary hematologic
parameters were in line with the confirmatory
results, showing similarity for all pair-wise com-
parisons, although no formal acceptance criteria
were predefined.
Immunogenicity of biologics is routinely
monitored in developmental clinical studies, but
it was not expected to see any signs of immuno-
genicity of the tested epoetin alfa products in this
4-week study comprising 12 intravenous in-
jections. Reports of anti-erythropoietin antibody
mediated pure red-cell aplasia (PRCA) have
generally been associated with extended periods
of subcutaneous administration of ESAs.[18] The
mean time to onset of epoetin-associated PRCA
from initiation of epoetin treatment has been re-
ported to be 9.3 months (range 0.3–84.3 months).
To date, no cases of PRCA have been reported in
patients who received only intravenous treatment
with ESAs.[19]
It can be assumed that the positive RIP results
in two subjects were probably due to unspecific
binding in this sensitive screening assay. Neither
of them had neutralizing antibodies that would
have affected the biologic response to study medi-
cation; both subjects completed the study and
were included in the pharmacokinetic and phar-
macodynamic analyses. There were no records of
any prior administration of ESAs for therapeutic
reasons or during a previous clinical study in
these two subjects. The frequency of detectable
anti-erythropoietin antibodies in the general
population has been suggested to be <0.2%[20]
and there are only a few reports in the literature
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of neutralizing anti-erythropoietin antibodies in
patients who have never been treated with re-
combinant ESAs.[21,22]
In summary, study part A confirmatorily
showed bioequivalence and pharmacodynamic
equivalence of HX575 and the US-marketed
Epogen, study part B sequentially demonstrated
equivalence of HX575-TT and HX575, of
HX575-TT and Erypo/Eprex, and the com-
parison across study parts demonstrated equiv-
alence of HX575-TT and Epogen.
Thus, the biosimilar epoetin alfa product
Binocrit, both from the original and from the
additional production site (i.e. HX575 and
HX575-TT), are bioequivalent with both epoetin
alfa products Epogen and Erypo/Eprex. This
clinical data confirm that the production process
for complex biologic molecules can be success-
fully transferred, despite ‘the process is the pro-
duct’ mantra. Moreover, our study data are
consistent with those of a previous intravenous
phase I study also comparing HX575 and Erypo/
Eprex[8] that indicates consistent standardiza-
tions of the analyzed epoetin alfa products leading
to reproducible results.
Conclusion
This first direct head-to-head comparison of
Epogen and Erypo/Eprex in a randomized
clinical trial setting indicates a remarkably high
degree of pharmacokinetic and pharmacodyna-
mic similarity of the US- and the European-
marketed epoetin alfa products. The use of
different stabilizers inUS-marketed versusEuropean-
marketed epoetin alfa products does not affect
the pharmacokinetic and pharmacodynamic pro-
perties, which are in line with previous findings.[4]
The observed high similarity of the pharmaco-
kinetic and pharmacodynamic profiles of all com-
pared products shows that therapeutic proteins
do not necessarily have to be identical to have
comparable clinical safety and efficacy profiles.
These findings can also be seen in line with the
regulatory agency’s position in Europe that mi-
nor structural differences in the active substance
between a biosimilar and the reference product
may be acceptable when satisfactorily justified.
The observed high degree of bioequivalence
and pharmacodynamic equivalence allows link-
ing and comparing data from clinical studies that
were conducted using either US- or European-
marketed epoetin alfa products. Since the clinical
bioavailability and pharmacodynamic potency of
all three compared epoetin alfa products are
similar, despite different formulations used in
Europe and the US, clinical study data produced
with a product sourced in Europe could be used
to support a marketing authorization in another
geographical/regulatory area.
Acknowledgments
The study was sponsored by Hexal AG (Industriestr. 25,
83607 Holzkirchen, Germany). Hexal is a Sandoz company.
Marite´ Ode and Karsten Roth are employees of Hexal
AG. Michael Lissy is an employee of Nuvisan GmbH (We-
generstrasse 13; D-89231 Neu-Ulm, Germany), the company
that conducted the study.
All authors were involved in the design and conduct of the
study, and the interpretation of the data. Moreover, all au-
thors have reviewed, contributed to, and approved the final
manuscript.
The following people (all employees of Hexal AG) made
substantial contributions but do not meet the criteria for
authorship: Stephan Parche managed the conduct of the
trial according to Good Clinical Practice guidelines; Gu¨nter
Silbernagl was the trial statistician; and Gabor Stiegler
prepared the draft manuscript.
References
1. Graber SE, Krantz SB. Erythropoietin and the control of
red cell production. Annu Rev Med 1978; 29: 51-66
2. Jelkmann W. Molecular biology of erythropoietin. Intern
Med 2004; 43 (8): 649-59
3. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-
associated pure red cell aplasia: past, present, and future
considerations. Transfusion 2008; 48 (8): 1754-62
4. Cheung WK, Natarajan J, Sanders M, et al. Comparative
pharmacokinetics, safety, and tolerability after subcuta-
neous administration of recombinant human erythro-
poietin formulated with different stabilizers. Biopharm
Drug Dispos 2000; 21 (6): 211-9
5. Epogen: US prescribing information. Thousand Oaks
(CA): Amgen Inc., 2010
6. Procrit: US prescribing information. Raritan (NJ): Cen-
tocor Ortho Biotech Products, L.P., 2009
7. Rhodes CT. Generic substitution: does interchangeability
mean equality of all functional relevant attributes? Clin Res
Reg Affairs 1995; 12 (4): 267-72
8. So¨rgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequiva-
lence of HX575 (recombinant human epoetin alfa) and a com-
parator epoetin alfa after multiple intravenous administrations:
74 Lissy et al.
ª 2011 Lissy et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (1)
an open-label randomised controlled trial. BMC Clin Phar-
macol 2009; 9: 10
9. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized,
controlled trial of darbepoietin alfa for the treatment of
anemia in hemodialysis patients. Am J Kidney Disease
2002; 40: 110-8
10. Cheung W, Minton N, Gunawardena K. Pharmacokinetics
and pharmacodynamics of epoetin alfa once weekly and
three times weekly. Eur J Clin Pharmacol 2001; 57 (5): 411-8
11. Chow SC, Liu JP. Design and anaylsis of bioavailabitlity and
bioequivalence studies. HongKong:MarcelDekker Inc., 1992
12. Data on file, Sandoz Biopharmaceuticals, 2010
13. Deechongkit S, Aoki KH, Park SS, et al. Biophysical com-
parability of the same protein from different manu-
facturers: a case study using epoetin-alfa from Epogen and
Eprex. J Pharm Sci 2006; 95: 1931-43
14. So¨rgel F, Thyroff-Friesinger U, Vetter A, et al. Biosimilarity
of HX575 (human recombinant epoetin alfa) and epoetin
beta after multiple subcutaneous administration. Int J Clin
Pharmacol Ther 2009; 47 (6): 391-401
15. So¨rgel F, Thyroff-Friesinger U, Vetter A, et al. Bioequiva-
lence of HX575 (recombinant human epoetin alfa) and a
comparator epoetin alfa after multiple subcutaneous ad-
ministrations. Pharmacology 2009; 83 (2): 122-30
16. Haag-Weber M, Vetter A, Thyroff-Friesinger U, on behalf
of the INJ-Study Group. Therapeutic equivalence, long-
term efficacy and safety of HX575 in the treatment of
anemia in chronic renal failure patients receiving hemo-
dialysis. Clin Nephrol 2009; 72 (5): 380-90
17. Weigang-Ko¨hler K, Vetter A, Thyroff-Friesinger U.
HX575, recombinant human epoetin alfa, for the treat-
ment of chemotherapy-associated symptomatic anaemia
in patients with solid tumours. Onkologie 2009; 32 (4):
168-74
18. McKoy JM, Robin E, Stonecash RE, et al. Epoetin-
associated pure red cell aplasia: past, present, and future
considerations. Transfusion 2008 Aug; 48 (8): 1754-62
19. Evens AM, Bennett CL, Luminari S. Epoetin-induced pure
red-cell aplasia (PRCA): preliminary results from the research
on adverse drug events and reports (RADAR) group. Best
Pract Res Clin Haematol 2005 Sep; 18 (3): 481-9
20. Tacey R, Greway A, Smiell J, et al. The detection of anti-
erythropoietin antibodies in human serum and plasma.
Part I: validation of the protocol for a radioimmunopre-
cipitation assay. J Immunol Methods 2003 Dec; 283 (1-2):
317-29
21. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Auto-
antibodies against erythropoietin in a patient with pure
red-cell aplasia. N Engl J Med 1996; 334: 630-3
22. Linardaki GD, Boki KA, Fertakis A, et al. Pure red cell
aplasia as presentation of systemic lupus erythematosus:
antibodies to erythropoietin. Scand J Rheumatol 1999;
28 (3): 189-91
Correspondence: Marite´ Ode, Sandoz Biopharmaceuticals,
Hexal AG, Industriestrasse 25, D-83607 Holzkirchen,
Germany.
E-mail: maria.ode@sandoz.com
PK and PD Comparison of US- versus European-Marketed Epoetin Alfas 75
ª 2011 Lissy et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (1)
